Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy-Reference-Cited by-同舟云学术

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy

Published:2008-09 Issue:9 Volume:9 Page:840-849
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Gnant Michael,Mlineritsch Brigitte,Luschin-Ebengreuth Gero,Kainberger Franz,Kässmann Helmut,Piswanger-Sölkner Jutta Claudia,Seifert Michael,Ploner Ferdinand,Menzel Christian,Dubsky Peter,Fitzal Florian,Bjelic-Radisic Vesna,Steger Günther,Greil Richard,Marth Christian,Kubista Ernst,Samonigg Hellmut,Wohlmuth Peter,Mittlböck Martina,Jakesz Raimund

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer;Jonat;Eur J Cancer,1995

2. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials;Klijn;J Clin Oncol,2001

3. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials;Cuzick;Lancet,2007

4. Cyclophosphamide, Methotrexate, and Fluorouracil Versus Tamoxifen Plus Ovarian Suppression as Adjuvant Treatment of Estrogen Receptor–Positive Pre-/Perimenopausal Breast Cancer Patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 Randomized Trial

5. Randomized Adjuvant Trial of Tamoxifen and Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil: Evidence for the Superiority of Treatment With Endocrine Blockade in Premenopausal Patients With Hormone-Responsive Breast Cancer—Austrian Breast and Colorectal Cancer Study Group Trial 5

Cited by 336 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer treatment-induced bone loss;The Korean Journal of Internal Medicine;2024-09-01

2. Multicenter Study on the Frequency of Low Bone Mineral Density in Young Women With Breast Cancer and Associated Factors;Clinical Breast Cancer;2024-08

3. Bone-active drugs in premenopausal women with breast cancer under hormone-deprivation therapies;European Journal of Endocrinology;2024-07-26

4. Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis;Cochrane Database of Systematic Reviews;2024-07-09

5. Denosumab Prevents Bone Loss and Microarchitectural Deterioration in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression Therapy: A Randomized Controlled Trial;Journal of Clinical Oncology;2024-07-02